Effect of statin therapy on colorectal cancer

Marc Bardou,¹ Alan Barkun,² Myriam Martel²

¹INSERM—Centre d'Investigations Cliniques Plurithématique 803 (CIC-P 803) and Service de Pharmacologie, Dijon, France

²Divisions of Gastroenterology and Clinical Epidemiology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada

Correspondence to

Marc Bardou, INSERM CIC-P 803, Faculté de Médecine, 7 bd Jeanne d'Arc, BP 87900, 21079 Dijon Cedex, France; marc.bardou@u-bourgogne.fr

Published Online First
26 July 2010

ABSTRACT

Hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also called statins, are commonly prescribed medications that lower serum cholesterol and decrease cardiac morbidity and mortality. They also possess beneficial effects beyond their cholesterol-lowering properties. Preclinical data suggest statins exhibit pleiotropic antineoplastic effects in a variety of tumours, but clinical studies have provided conflicting data as to whether statins influence the risk of cancer. The biological underpinning of potential effects of statins in colorectal cancer and their role in its prevention or as adjuvant therapy are reviewed. Following a meta-analysis of both randomised clinical trials and epidemiological studies, it is concluded that available clinical data only support a modest, although statistically significant, protective effect of statins in colorectal cancer. Statins may impact on outcomes by decreasing the invasiveness or metastatic properties of colorectal cancer. The data supporting these hypotheses, however, are few and further studies are required to better assess these hypotheses. Statins may also exert a beneficial effect on colorectal cancer by sensitising the tumour to chemotherapeutic agents. Further research is needed to better define the role of statins in overcoming chemoresistance. The combination of statins with other drugs, such as low-dose aspirin or safer non-steroidal anti-inflammatory medications, may be useful in both the prevention and treatment of colorectal cancer.

INTRODUCTION

In Western countries, the cumulative lifetime risk of developing colorectal cancer (CRC) approximates 5% in the general population.¹ Moreover, CRC remains the third leading cause of cancer-related death after lung and prostate cancers in men and lung and breast cancers in women, in the United States.² The 10–15 years required for an adenomatous polyp to evolve into clinically invasive cancer in most patients,³ and the favourable prognosis of cancers detected at early stages, have both justified the important role of screening, with different means, in this condition.⁴ Faecal occult blood testing (FOBT) reduces the risk of CRC mortality by 16% (RR 0.84, 95% CI 0.78 to 0.90).⁵ The protective effect is even greater (RR 0.75, 95% CI 0.66 to 0.84) for those attending at least one round of screening using FOBT. Alternate preventative strategies have included chemoprevention, which involves the long-term use of a variety of oral agents that can delay, prevent, or even reverse the development of adenomas in the large bowel, and interferes with the multistep progression from

adenoma to carcinoma. Chemoprevention is of particular importance to individuals with a hereditary predisposition to colorectal neoplasia^{6 7} and to those who are especially susceptible to the environmental triggers of CRC.

Statins exert their effects through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). HMG-CoA reductase catalyses the conversion of HMG-CoA into mevalonate in the mevalonate biosynthetic pathway, the rate-limiting step in the cholesterol biosynthetic pathway.⁸ Statins, by inhibiting cholesterol biosynthesis, emerged as one of the most important drugs responsible for lowering the incidence of cardiovascular disease, even in apparently healthy persons without hyperlipidaemia but with increased high-sensitivity C-reactive protein levels.^{9 10} In addition to reducing cholesterol levels, statins inhibit the generation of other products of the mevalonate pathway, including mevalonate and the downstream isoprenoids (farnesyl pyrophosphate and geranylgeranyl pyrophosphate). Post-translational isoprenylation is important in determining the membrane localisation and function of many cellular proteins, including small GTPases such as Ras and Rho.¹¹ This pathway, with its potential roles in carcinogenesis, is summarised in figure 1. Because Ras mutations are frequent in tumours,¹² and Rho proteins participate in growth-factor signalling,¹³ the study of the action of statins in tumour cells has largely focused on their ability to inhibit small GTPases,¹⁴ even if there is evidence that this may not be the only mechanism by which statins may inhibit proliferation and induce apoptosis. On the other hand, since cholesterol is the main structural component of cell membranes, any compound decreasing cholesterol may in turn affect various cellular events and impair homeostasis. This hypothesis has been supported by the observed increases in both non-cardiovascular-related mortality following statin therapy, and cancer risk in patients with low cholesterol levels.¹⁵ Even if these findings have since been challenged,^{16 17} the possible effect of statins on the incidence of various cancers has been assessed as part of safety analyses of cholesterol lowering trials and will also be addressed.

METHODS FOR THE META-ANALYSIS

Search strategy

We performed a comprehensive search on a possible relationship between statins and colorectal or digestive tumours by searching EMBASE, MEDLINE, CENTRAL and the ISI Web of

Figure 1 Mevalonate pathway. Statins inhibit the conversion of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) to mevalonate. Mevalonate is then phosphorylated to form pyrophosphomevalonate, which is then converted to isopentenyl pyrophosphate (isopentenyl-PP). Isopentenyl-PP and dimethylallyl pyrophosphate (dimethylallyl-PP) can then be combined to form the 10-carbon isoprenoid geranyl pyrophosphate (geranyl-PP). Additional isopentenyl-PPs can be added to produce farnesyl pyrophosphate (farnesyl-PP), the 15-carbon isoprenoid, and geranylgeranyl pyrophosphate (geranylgeranyl-PP), the 20-carbon isoprenoid. Inhibition of this pathway by statins prevents the formation of both mevalonate and its downstream product, isopentenyl-PP. Several other branches of this pathway can convert farnesyl-PP into various other products, including cholesterol. In general, farnesyl-PP helps prenylate proteins in the Ras family, whereas geranylgeranyl-PP helps prenylate proteins in the Rho and Rac families. Ras, Rho and Rac proteins have several physiological functions potentially involved in carcinogenesis.

knowledge. The identification of articles was developed using a highly sensitive search strategy to identify reports with a combination of controlled vocabulary and text words related to: (1) statin (hydroxymethylglutaryl-CoA reductase inhibitor, pravastatin, simvastatin, atorvastatin, rosuvastatin, fluvastatin, mevastatin); and (2) cancer (carcinoma, adenoma, tumour, polyp, lesion). In addition recursive searches and cross-references were carried out using a 'similar articles' function and hand searches of articles identified after an initial search. We included all adult human studies in French or English and included abstracts, spanning the last 10 years up to September 2009. In the case of studies with incomplete information, we attempted to contact authors to obtain additional data.

Inclusion criteria

We included the following types of articles: (1) randomised clinical trials, case-control and cohort studies that either assessed or reported colorectal, digestive, gastrointestinal, colon and rectal cancer prevalence in subjects taking, or not taking, statins; and (2) articles that contained sufficient detail to reconstruct 2×2 tables expressing colorectal cancer prevalence by statin intake status. Since randomised clinical trials assessed primary cardiovascular outcomes and were not designed to

assess CRC, full papers were manually reviewed (MB and MM), to search for CRC data.

Exclusion criteria

We excluded all studies whose designs did not fulfil inclusion criteria, studies not published in English or French, studies without specific cancer site assessment, and studies not assessing digestive tract cancers. If more than one study was included from the same author, we carefully assessed the absence of overlap by using the recruitment periods noted in the manuscript or by contacting the author if the report did not provide these data.

The data were extracted by two independent reviewers (MB and MM) with discrepancies settled by a third investigator (AB). Analyses were first performed separately for randomised controlled trials, and cohort or case-control studies, and then altogether as previously reported by Shrier *et al*¹⁸ who suggested that the advantages of including both observational and randomised studies in a meta-analysis could outweigh the disadvantages in many situations, and that observational studies should not be excluded *a priori*. To quantify the strength of any observed association, we used the Mantel-Haenszel method from the 2×2 tables defined by the statin group and the incidence of colorectal cancer for the randomised controlled trials. For observational studies, we preferred the

multiple risk factor adjustment to the crude risk ratio. The estimates of risk ratio were transformed to their natural logarithm before pooling and the variance was calculated by $((\ln(\text{upper CI RR}) - \ln(\text{lower CI RR}))/3.92)^2$.¹⁹ Fixed effect models were applied to all comparisons to determine corresponding overall effect sizes and their confidence intervals, unless heterogeneity was noted, in which case a random effect model was employed. The Higgins I-squared statistic was calculated to quantify the proportion of variation in treatment effects attributable to between-study heterogeneity. Values of I-squared equal to 25%, 50% and 75% represent low, moderate and high heterogeneity, respectively. The presence of heterogeneity across studies was defined using a χ^2 test of homogeneity with a 0.10 significance level. To better characterise possible sources of statistical heterogeneity, sensitivity analyses were carried out excluding studies one-by-one. We performed all meta-analyses using the RevMan 5 software.

STATINS AND THE PREVENTION OF COLORECTAL CANCER

What is the rationale supporting a potential protective effect of statins against CRC?

Several mechanisms may be responsible for an antitumour effect of statins, including induction of apoptosis, inhibition of cell growth or angiogenesis or enhancement of immune response.²⁰

Apoptosis

Colorectal cancer is thought to originate in the expansion of colonic crypt cells as a result of aberrant gene expression caused by transcription factors of the T-cell factor (TCF)/ β -catenin family.²¹ Many of the genetic errors that accumulate during colorectal carcinogenesis affect the control of apoptosis, and many studies have shown that colorectal carcinogenesis is related to the inhibition of apoptosis and the augmentation of proliferative activity.²² Effective chemoprevention strategies for colorectal cancer must thus target these genetic defects and promote or restore apoptosis. Mutation of the APC gene is often the initiating genetic lesion observed in colorectal cancers.²³ Depending on the cellular context, loss of APC activates the Wnt signalling pathway, causing immediate widespread apoptosis of colorectal epithelial cells and defects in differentiation and cell migration. Only cells that are inherently resistant to apoptosis survive this initial wave of apoptosis. These surviving cells constitute the epithelial population that develops into adenomas. Two gene targets of the Wnt signalling pathway are of particular relevance to apoptosis: survivin^{24–26} and the proto-oncogene c-MYC.^{27–29} Although controversial, survivin may enhance cell proliferation and inhibit apoptosis,^{26–30} and is overexpressed in colorectal carcinomas.³¹ c-MYC in normal cells is involved with both the induction of apoptosis and cell proliferation. As these are opposing functions,

c-MYC can only induce cell proliferation if apoptosis has first been disabled.

Statins have been shown to induce apoptosis through both extrinsic and intrinsic pathways, leading to cell death.^{32–35} Although the mechanism of statin-induced apoptosis has not been fully elucidated, statin-induced apoptosis is likely due to the depletion of geranylgeranylated or farnesylated proteins, which may be dependent on cell type or the state of differentiation (see figure 2).³⁶

Experiments conducted in spontaneously immortalised rat intestinal epithelial cells, IEC-18 and their K-ras transformed clones, have shown that lovastatin induces morphological changes and apoptosis (not influenced by K-ras mutations), by inhibiting geranylgeranylation of small GTPases of the rho family, thereby inactivating these.³² Shibata *et al* showed, in a mouse model of metastatic mammary cancer carrying a p53 mutation, that lovastatin induced both a decrease in DNA synthesis and an increase in apoptosis.³⁷ Although this study was not performed on colorectal cancer cells, it suggests a p53-independent pathway, which is of particular interest since APC, K-ras, Smad4 (or DPC4-deleted in pancreatic cancer 4) and p53 genes have all been incriminated in CRC. Nevertheless there are, to our knowledge, no data suggesting that the effect of statins on CRC may depend on K-ras activation status.

More recently, Cho *et al* showed that simvastatin induces apoptosis in human colorectal cancer COLO 205 and HCT 116 cell lines in a dose and time-dependent manner, and down-regulates the expression of antiapoptotic proteins Bcl-2, Bcl-xL, cIAP1 and cFLIP.³³ These authors also showed that simvastatin is able to reduce tumour development in a colitis-associated colon cancer (CAC) model in C57/BL6 mice.³³ In addition they inoculated subcutaneously 5×10^6 COLO205 cells into BALB/c nu/nu mice, to develop a xenograft model, and observed that tumours from animals treated with simvastatin had smaller volumes, larger necrotic areas, lower expression of VEGF and higher apoptotic scores compared to controls.³³ Simvastatin may thus have the potential to inhibit CRC development by inducing apoptosis and suppressing angiogenesis. Using an experimental (APC^{Min} mice) model for familial adenomatous polyposis, Swamy *et al*³⁸ showed that atorvastatin and celecoxib were both able to induce apoptosis in CRC, with a trend towards a more pronounced effect with atorvastatin. Conversely, Xiao *et al*³⁴ reported that neither atorvastatin nor celecoxib were able to induce apoptosis in two human colon cancer cell lines (HCT116 and HT29), whereas the combination of both drugs induced apoptosis, but only after a treatment of 48 h or more.³⁴ This apparent discrepancy might be explained by the differing sensitivities of CRC cell lines to statin treatment.³⁹

The BMP (bone morphogenetic protein) pathway has recently been implicated in CRC with the identification of germline mutations in BMPR1a and SMAD4 in families with familial juvenile polyposis syndrome.⁴⁰ Affected individuals

Figure 2 Suggested effect of statin on mitochondria-mediated apoptotic signalling. HMG-CoA reductase inhibition by statins increases cytosolic calcium concentration and expression of the pro-apoptotic protein Bax. Bax in turn inhibits complex I of the mitochondrial respiratory chain (RC). This depolarises the inner membrane ($\Delta\psi$) triggering a calcium release through the mitochondrial transition pore (MTP) and sodium calcium exchanger (SCE). Cytochrome c (Cyt C) release from the mitochondria leads to activation of procaspase-9. Active caspase-9 cleaves and activates procaspase-3, which leads to apoptosis.

exhibit a greatly increased risk of developing cancer.^{41 42} BMP2 is a promoter of apoptosis in mature epithelial cells in the colon,⁴³ and Kodach *et al*³⁹ have shown that statin-sensitive CRC cell lines show inductions of both the BMP pathway and the BMP target gene ID-2. These authors suggested that the beneficial or deleterious effects of statins might depend on the CRC cells line, since they observed in a xenograft mouse model that simvastatin induced inhibition of tumour growth when using sensitive cells, while it promoted tumour growth when insensitive cells were used.³⁹

Kaneko *et al*⁴⁴ reported that lovastatin induces apoptosis in the human colon cancer cell line SW480 by blocking the cholesterol synthesis pathway. They observed that, among all antiapoptotic proteins that were assessed, survivin was the only one to be down-regulated by lovastatin. Furthermore, farnesyl pyrophosphate and geranylgeranyl pyrophosphate (see figure 1) simultaneously reversed surviving down-regulation, indicating that the effects of statins are indeed mediated through HMG-CoA reductase inhibition.⁴⁴

To summarise, statins can, at least theoretically, oppose colorectal cancer growth by inducing apoptosis, through a down-regulation of anti-apoptotic proteins such as Bcl2 or cIAP1 and an up-regulation of proapoptotic proteins such as BMP, and inhibiting tumour angiogenesis.

Inhibition of cell proliferation

Cell proliferation in the upper part of colonic crypts is a premalignant marker,⁴⁵ and inhibition of cancer cell proliferation through HMG-CoA reductase inhibition and isoprenoids depletion (figure 1) has been one of the mechanisms implicated in the anticancer effect of statins. For example, Hong *et al*⁴⁶ showed that lovastatin decreases cellular proliferation in HCT-116 and HT-29 human colon cancer cells. This effect, mediated through a G0/G1 cell cycle arrest, was also described for mevastatin and atorvastatin⁴⁷ in Caco-2 colorectal cancer cell lines.⁴⁸ It has been reported, although not in colorectal cancer cells but in breast cancer cells, that cerivastatin treatment modified the expression of 13 genes that may contribute to the inhibition of both cell proliferation and invasion, either directly or indirectly by stimulating an anti-angiogenic gene, an effect mainly explained by the inhibition of RhoA-dependent cell signalling.⁴⁹ It is important to note, however, that a statin-induced effect such as the inhibition of cell proliferation, may not be generalisable to other cancer cell lines.⁵⁰

Inhibition of angiogenesis

Angiogenesis is indispensable for the growth of solid tumours, and without the supply of new blood vessels, the size of a tumour can only reach a volume of about 2 mm³.⁵¹ It has been suggested

that angiogenic switch occurs at the onset of dysplasia in the adenoma carcinoma sequence.⁵² Targeting the formation of blood vessels is therefore regarded as a promising strategy in cancer therapy. Statins exhibit both pro-angiogenic effects, which are regarded as beneficial for the treatment of cardiovascular diseases, and anti-angiogenic activities that can be of particular importance in anti-cancer therapy. Although most of the studies were not performed in cancer models, some mechanisms have been suggested underlying the pro- or anti-angiogenic effects of statins, including an increase in bone marrow-derived endothelial progenitor cells or activation of Akt and nitric oxide synthase.⁵³ It has been suggested that low statin doses induce a pro-angiogenic effect, whereas high statin doses may decrease protein prenylation and inhibit cell growth.⁵⁴ Additionally, the same dose of a given statin may either promote or inhibit angiogenesis based on the presence of other angiogenesis promoters, such as hypoxia or TNF.⁵⁵ Moreover, the statin-mediated inhibition of vascular endothelial growth factor (VEGF) synthesis, the major angiogenic mediator, may contribute to the attenuation of angiogenesis. Pravastatin has also been shown, using human umbilical vein endothelial cells, to induce a dose-dependent decrease in the proliferative activity of endothelial cells, which is dependent on the cell cycle arrest to the G1 phase and not on cell apoptosis.⁵⁶ There exist few data supporting the anti-angiogenic role of statin therapy in CRC. Cho *et al*³³ assessed the anti-angiogenic effect of simvastatin using anti-VEGF antibody in a xenograft model where human colorectal cancer cells (COLO205) were inoculated subcutaneously into mice. They found that simvastatin suppressed VEGF expression both in vitro and in vivo, and suggested that simvastatin inhibits VEGF-mediated angiogenesis via the NF- κ B pathway.³³

Decrease in metastatic capacity

It has been suggested that the Rho family of small GTPases plays a role in growth and metastatic capacity of various tumours, such as colorectal

cancer.^{57 58} A few years ago, Nubel *et al*⁵⁹ showed that lovastatin significantly blocked cytokine-induced adhesion of colon cancer cells to primary human endothelial cells (HUVEC) and that this effect was mediated through an inhibition of Rho-regulated expression of E-selectin by TNF. This is of particular interest since it has been suggested that E-selectin plays an important role in the attachment of tumour cells to the endothelium during the process of metastasis as it has been shown to be crucial not only for initial adhesion and rolling of circulating HT-29 colon cancer cells on the endothelium but also for their subsequent diapedesis.⁶⁰ Statins inhibit Rho activation (see figure 1) and have been shown, for example in an in vitro model of pancreatic cancer invasiveness, to inhibit cancer cell invasion induced by epidermal growth factor (EGF), in a manner sensitive to C3 transferase, a specific inhibitor of Rho.⁶¹ Additionally, using an in vivo model of hepatocellular carcinoma in rats, Parag *et al*⁶² have shown that fluvastatin had a dose-dependent inhibitory effect on primary and metastatic tumours, and that the inhibitory effect on growth was more pronounced in metastases than in primary tumours. Nevertheless, convincing data showing a statin-induced decrease in metastatic capacity of colorectal cancer are scarce.

All the aforementioned effects, that may explain in part the beneficial effects of statins in CRC, are largely overlapping, and additional effects, such as the modulation of inflammation or immune responses, may also play important roles. The latter are controversial since statins affect multiple cell populations relevant to the immune response, including B cells, T cells, regulatory T cells, macrophages and dendritic cells; some favour immune tolerance while others an immune response role.

Is there clinical evidence supporting a protective effect of statins in CRC?

The association between statin use and CRC occurrence remains controversial. Following the observations that simvastatin or pravastatin exhibited chemopreventive effects in colon carcinogenesis,⁶³ many studies have since explored the effect of statins, reaching disparate conclusions. However, most of the results from randomised clinical trials were obtained from studies that were not primarily designed and powered to assess the role of statin in CRC prevention.

Several meta-analyses have been published in the past few years; most have not concluded whether or not there is a protective effect of statins in CRC.^{64–69}

Our literature search using the following MeSH terms identified 4002 citations for a final inclusion of 32 studies. MeSH terms used: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Statins; HMG-CoA reductase inhibitors; Pravastatin; Simvastatin; Atorvastatin; Rosuvastatin; Fluvastatin; Mevastatin; Colorectal Neoplasms; Carcinoma; Adenoma; Tumor; Polyp; Cancer; Lesion. Figure 3 presents the QUORUM diagram.

Randomised clinical trials

We retrieved 930 references and identified 11 studies, with a total of 95 984 patients (47 884 in

Figure 3 QUORUM diagram.

Table 1 Randomised controlled trials included in the meta-analysis

Study	Patient population	Study type	Statin used	Control	Duration of recruitment (years)	Duration of follow-up (years)	No. of included patients	CC event/total statin group	CC event/total control group
Shepherd, (WOSCOP) 1995 ⁹⁰	Men aged 45–65 with a mean ($\pm$ SD) plasma cholesterol level of 272 ± 23 mg/dl (7.0 ± 0.6 mmol/l)	Randomised double-blind	Pravastatin 40 mg daily	Placebo	1989–91	4.9 (mean) Final visit: 1995	6595	31/3293	30/3302
Sacks, (CARE) 1996 ⁹¹	Patient with myocardial infarction who had plasma total cholesterol levels < 240 mg/dl (mean 209) and LDL cholesterol levels of 115 to 174 mg/dl (mean 139)	Randomised double-blind	Pravastatin 40 mg daily	Placebo	1989–91	5.0 (median) Final visit: 1996	4159	12/2081	21/2078
(LIPID) 2002 ⁹²	Patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol of 4.0 – 7.0 mmol/l	Randomised double-blind for primary study, then open-label	Pravastatin 40 mg daily	Placebo	1990–92	6.0 (mean) double-blind period Extended follow-up: 2.0 (mean) Final visit: 1997	9014	75/4512	71/4502
Downs, (AFCAPS) 1998 ⁹³	Patients with average TC and LDL-C	Randomised double-blind	Lovastatin 20–40 mg daily	Placebo	1991–93	5.2 (mean) Final visit: 1997	6605	25/3304	20/3301
(ALLHAT-LLT) 2002 ⁹⁴	and below-average HDL-C as characterised by the NHANES* Patients aged ≥ 55 years, with LDL-C of 120 – 189 mg/dl (100 – 129 mg/dl if known CHD) and triglycerides < 350 mg/dl	Randomised, non-blinded	Pravastatin 40 mg daily	Usual care	1994–2002	4.8 (mean) Study closeout: 2002	10355	46/5170	38/5185
Shepherd, (PROSPER) 2002 ⁹⁴	Patients aged 70–82 years with history of, or risk factors for, vascular diseases	Randomised double-blind, placebo controlled trial	Pravastatin 40 mg daily	Placebo	1997–1999	3.2 (mean) Study closeout: 1999	5804	65/2839	45/2869
(HPS), 2002 ⁹⁵	Patients aged 40–80 years with coronary disease, other occlusive arterial disease or diabetes	Randomised	Simvastatin 40 mg daily	Placebo	1994–97	5.0 (mean) Final visit: 2001	20536	114/10269	131/10267
Strandberg, (4S) 2004 ⁹⁶	Patients with CHD, serum TC 5.5 – 8.0 mmol/l, and serum triglycerides ≤ 2.5 mmol/l	Randomised double-blind	Simvastatin 20 mg daily; 40 mg daily in patients who did not reach the target total cholesterol concentration of 3.0 – 5.2 mmol/l after 6–18 weeks	Placebo	1988–89	10.4 (median) Final visit: 1999	4444	25/2221	32/2223
Colhoun, (CARDS) 2004 ⁹⁷	Patients aged 40–75 years, no documented previous history of cardiovascular disease, an LDL-cholesterol of ≤ 4.14 mmol/l, a fasting triglyceride of ≤ 6.78 mmol/l, and at least one of the following: retinopathy, albuminuria, current smoking or hypertension	Randomised	Atorvastatin 10 mg daily	Placebo	1997–2001	3.9 (median) Final visit: 2003	2838	20/1428	30/1410
Nakamura, (MEGA) 2006 ⁹⁸	Patients with hypercholesterolaemia (total cholesterol 5.69 – 6.98 mmol/l) and no history of coronary heart disease or stroke	Prospective, randomised, open-labelled, blinded study	Diet + Pravastatin 10–20 mg daily	Diet	1994–99	5.3 (mean) Final visit: 2004	7832	58/3866	65/3866
Ridker, 2008 ¹⁰	Healthy men and women with LDL cholesterol of < 130 mg/dl (3.4 mmol/l) and high-sensitivity C-reactive protein levels of ≥ 2.0 mg/l	Randomised, double-blind	Rosuvastatin 20 mg daily	Placebo	2003–06	1.9 (median) Final visit 2008	17802	333/8901	372/8901

C, cholesterol; CC, case-control; CHD, coronary heart disease; HDL, high density lipoprotein; LDL, low density lipoprotein; TC, total cholesterol.

Figure 4 Forrest plot: results from individual studies and meta-analyses of randomised clinical trials. The risk ratio and 95% CI for each study are displayed on a logarithmic scale. Pooled estimates are from a fixed-effect model.

the treatment and 48 004 in the control group) that were included in the analysis (table 1). Pooled analysis showed a modest trend towards a protective effect of statins against the occurrence of CRC (RR 0.94; 95% CI 0.86 to 1.04, $p=0.23$) that failed to reach statistical significance (figure 4)—a result consistent with that of the meta-analyses of Dale *et al*⁶⁵ and Bonnovas *et al*,⁶⁷ who also found non-significant odds ratios of 1.02 and 0.95, respectively.

The test for heterogeneity was 0%, indicating no variability between studies that cannot be explained by chance, and funnel plot analysis did not reveal significant publication bias. In sensitivity analysis, only the removal of the ALLHAT-LLT⁷⁰ trial had a significant impact on the RR which then reached statistical significance (0.90 (0.81 to 0.99)) without clear explanation, except that it was the only non-blinded study. Although it has been suggested that different statins might not interfere with cell cycle and apoptosis to the same extent,^{71 72} none of the assessed statins (pravastatin, lovastatin, simvastatin, atorvastatin and rosuvastatin) appeared to differ in their impact on CRC risk. Overall, 667 patients need to receive long term statin therapy to prevent one CRC. Importantly, even if all but one study had a treatment/follow-up of more than 4 years, most of these clinical trials were not designed to assess CRC incidence, and the duration of follow-up may have been too short. Our meta-analysis did not suggest any trend associating treatment duration and risk reduction for CRC, but most of the studies exhibited a follow-up of about 5 years, with only two extending beyond 8 years. The observed incidence ratio of CRC brings into question the feasibility of a clinical trial dedicated to this question.

Observational studies

From the 930 references retrieved, we included 13 case-control (821 416 patients) and 8 cohort studies (784 818 patients). Details of the studies are presented in tables 2 and 3, respectively.

We assessed case-control studies separately and found that statin use was associated with

a significant, although modest risk reduction in CRC risk (adjusted RR (aRR) 0.92, 95% CI 0.90 to 0.94, $p<0.001$) (figure 5). No heterogeneity was found among studies, and sensitivity analysis did not suggest that the omission of any of the included studies altered the magnitude of the observed effect.

When assessing cohort studies, significant heterogeneity was observed, with a non-significant trend towards a small risk reduction of CRC among statin users (aRR 0.89, 95% CI 0.75 to 1.05, $p=0.16$) (figure 6). Only the removal of the study by Singh *et al*,⁷³ the only study with a significant increased risk for CRC in statin exposed compared to non-exposed patients (RR 1.13, 95% CI 1.02 to 1.25), had a significant impact on the observed RR of CRC among statin users, that just reached statistical significance (aRR 0.84, 95% CI 0.71 to 1.00). When pooling case-control and cohort studies together, despite significant heterogeneity, a small but significant risk reduction of CRC in statin users was noted (RR 0.82, 95% CI 0.87 to 0.98).

Finally we combined randomised clinical trials and observational studies (31 studies, 2 552 943 patients) and found a 9% risk reduction in CRC risk (aRR 0.91, 95% CI 0.87 to 0.96, $p<0.001$) (figure 7).

Summary

It appears that combination of both randomised clinical trials and observational studies suggests a small impact on CRC occurrence attributable to chronic statin use. The numbers needed to treat (NNT) are correspondingly modest (varying from ~ 670 to 4800). These estimates have to be compared to that of statin therapy in cardiovascular prevention where the five-year NNT to prevent heart attack or stroke for statins in people with an annual risk of 3% is about 20. Hundreds of thousands of people would have to be enrolled in randomised trials to demonstrate a protective effect of statin therapy against CRC. Thus available data do not support the recommendation of chronic statin use to prevent CRC occurrence in patients at low or intermediate risk for CRC and there are no data available in high-risk

Table 2 Case-control studies included in the meta-analysis

Study	Patient population	Study type	No. of included patients	Statin use in CC cases	No statin use in CC controls	Adjusted RR (95% CI)
Blais, 2000 ⁹⁹ ✕	Cancer free patients for at least 1 year at cohort entry, 65 years and older, and treated with lipid-modifying agents	C-C/article	5962	56	560	0.83 (0.37 to 1.89)
Kaye, 2004 ¹⁰⁰	Patients 50–89 years old who used antihyperlipidaemic drugs or had a recorded diagnosis of untreated hyperlipidaemia Excluded patient diagnosed with any cancer other than the study cancer diagnoses	C-C/article	18088	25 (colon) 23 (rectal)	115 (colon) 59 (rectal)	1.0 (0.6 to 1.7) (colon) 1.6 (0.9 to 2.8) (rectal)
Graaf, 2004 ¹⁰¹	Included all patients with one or more prescriptions for cardiovascular drugs	C-C/article	20105	Not indicated	Not indicated	0.87 (0.48 to 1.57) (colon) 0.48 (0.16 to 1.48) (rectum) Pooled 0.76 (0.45 to 1.29)
Khurana, 2004 ¹⁰² ✕	Not indicated	C-C/abstract	534273	2453	2886	0.94 (0.89 to 1.00)
Poynter, 2005 ¹⁰³	Patients were eligible for participation if they had received a diagnosis of colorectal cancer between 31 May 1998 and 31 March 2004, and lived in a geographically defined area of northern Israel	C-C/article	3968	120	354	0.53 (0.38 to 0.74)
Rubin, 2005 ¹⁰⁴	Patients aged ≥18 years with newly diagnosed colorectal cancer. Non-IBD and IBD populations	C-C/abstract	38724	18440	368800	0.92 (0.89 to 0.96)
Coogan, 2007 ¹⁰⁵	Patients aged 50–74 years, spoke English, were physically and cognitively able to complete a telephone interview and a self-administered food-frequency questionnaire, and had received a first diagnosis of primary colorectal cancer	C-C/article	3618	457	523	0.92 (0.78 to 1.09)
Vinogradova, 2007 ¹⁰⁶	All patients with an incident colorectal cancer during the 10-year study period	C-C/article	30668	538	2424	0.93 (0.83 to 1.04)
Yang, 2008 ¹⁰⁷	Patients >50 years of age and with >5 years of colorectal cancer-free Initial follow-up in the General Practice Research Database	C-C/article	48724	NA	NA	1.1 (0.5 to 2.2)
Boudreau, 2008 ¹⁰⁸	Patients >40 years, diagnosed with colorectal cancer	C-C/article	1330	60	54	1.02 (0.65 to 1.59)
Robertson, 2008 ¹⁰⁹	Patients diagnosed with colorectal cancer; excluding those with evidence of statin use within one year of index date	C-C/abstract	83512	NA	NA	0.86 (0.75 to 0.99)
Shadman, 2009 ¹¹⁰	Women with colorectal cancer aged 50–74 years	C-C/article	2044	36	81	1.17 (0.74 to 1.85)
Hachem, 2009 ¹¹¹	We excluded patients who had a diagnosis of cancers of the pancreas, stomach, lung, oesophagus, liver and breast before index colorectal cancer diagnosis date	C-C/article	30400	NA	NA	0.91 (0.86 to 0.96)

CC, case-control.

patients with familial adenomatous polyposis (FAP) or Lynch syndrome.

Limitations of non-randomised studies relate to the possible influence of known and unknown factors that may affect outcome and be unequally distributed among cases and controls. One of the most obvious confounding factors, in the case of CRC, relates to lifestyle habits, like smoking and drinking, and dietary risk factors like meat, fat and fruit/vegetables consumption which are likely to be

related both to the exposure, statin use, and the outcome, of CRC occurrence. Most of these factors are often unlikely to be captured in population databases, making adjustment unfeasible. One of the limitations of the randomised controlled trials that were included in the meta-analysis is that they were not designed to assess cancer incidence and survival, leading to possible inaccuracies in CRC incidence reporting, that may not necessarily have been equally distributed in both groups.

Table 3 Cohort studies included in the meta-analysis

Study	Patient population	Study type/publication type	No. of included patients	Statin use in CC cases	No statin use in CC controls	Adjusted RR (95% CI)
Friis, 2005 ¹¹²	Patient aged 30–80, excluded individuals with a history of cancer (except non-melanoma skin cancer) before study entry	Cohort/article	334754	55	2951	0.85 (0.65 to 1.11)
Jacobs, 2006 ¹¹³	All adults, excluding history of colorectal cancer	Cohort/article	132136	183	601	1.03 (0.85 to 1.26)
Setoguchi, 2007 ¹¹⁴	Patients aged ≥65 years, excluded if they had a previous diagnosis of a cancer	Cohort/article	31723	190	59	1.96 (0.70 to 1.31)
Singh, 2009 ⁷³	Those with prior history of colorectal cancer were excluded	Cohort/article	35739	Not indicated	Not indicated	1.22 (1.11 to 1.35)
Karp, 2008 ¹¹⁵	Patients ≥45 years and discharged from the hospital alive after admission for acute myocardial infarction were included	Cohort/article	30076	61	173	0.58 (0.43 to 0.78)
Farwell, 2008 ¹¹⁶	Patients ≥18 years, excluding all patients with a cancer diagnosis on the cohort entry date	Cohort/article	62842	316	371	0.65 (0.55 to 0.78)
Flick, 2009 ¹¹⁷	Men aged 45–69 years old without a known history of cancer (exception of non-melanoma skin cancer)	Cohort/article	69115	56	115	0.89 (0.61 to 1.30)
Haukka, 2009 ¹¹⁸	All individuals residing in Finland who have purchased at least one prescription of any statin and had no cancer diagnosis at the date of the first purchase	Cohort/article	944962	1486	1464	0.99 (0.92 to 1.06)

CC, case-control.

Figure 5 Forrest plot: results from individual studies and meta-analyses of case-control studies. The risk ratio and 95% CI for each study are displayed on a logarithmic scale. Pooled estimates are from a fixed-effect model.

Is there clinical evidence supporting a protective effect of statins against colorectal adenomas?

Although the data supporting a protective effect of chronic statin use in CRC are not very conclusive, colorectal carcinogenesis is a multi-step process. The relationship between statin use and colorectal adenomas, an earlier step, has thus also been questioned. Surprisingly only few data are available to address this issue.

Statins and adenoma occurrence

In a secondary analysis of data from three large colorectal adenoma chemoprevention trials, statin use was not associated with a reduced adenoma risk (1.03, 95% CI 0.87 to 1.23), nor was it associated with decreased risks of advanced adenoma (1.13, 95% CI 0.70 to 1.81) or multiple adenomas (1.25, 95% CI 0.95 to 1.65).⁷⁴

A case-control study published in abstract form in 2007 evaluated whether self-reported use of statin was associated with a reduced incidence of colorectal adenomas.⁷⁵ Data from 1570 subjects (554 cases and 1016 controls), of whom 35.1% reported regular use of statin medications over the previous 5 years, were analysed. No significant association was found linking statin use to

a decreased occurrence of colorectal adenomas (adjusted OR 0.96, 95% CI 0.77 to 1.21). On the other hand it was also reported, in a small cohort study published only in abstract form in 2006, that patients using statin were more likely to be diagnosed with adenomatous polyps (118/227, 52%) compared to patients not taking a statin (186/452, 41%) (OR 1.55, 95% CI 1.12 to 2.13).⁷⁶ These results must be considered with great caution as they remain unpublished as a full paper, and adenoma prevalence was very high.

Statin and prevention of adenoma recurrence

Siddiqui *et al*⁷⁷ recently identified 2626 patients (84% men, mean age 62.2 years) through a review of endoscopy and pathology databases with adenomatous polyps removed at an index colonoscopy who had undergone a follow-up colonoscopy 3–5 years later. Statin use was assessed through a review of medical and pharmacy records. Overall, 583 of 1688 patients (35%) who used statins continuously had an adenoma found on follow-up colonoscopy, compared to 477 of 938 patients (51%) who did not (OR 0.51, 95% CI 0.43 to 0.60, $p < 0.01$). From this study, the number needed to treat with a statin to avoid an adenoma was

Figure 6 Forrest plot: results from individual studies and meta-analyses of cohort studies. The risk ratio and 95% CI for each study are displayed on a logarithmic scale. Pooled estimates are from a random-effect model.

Figure 7 Forrest plot: results from individual studies and meta-analyses of all 34 randomised clinical trials and observational studies. The risk ratio and 95% CI for each study are displayed on a logarithmic scale. Pooled estimates are from a random-effect model.

calculated as 6–7. Statins were also associated with decreased polyp numbers (2.6 vs 3.1, $p=0.002$), smaller polyp size (7.1 vs 7.9 mm, $p=0.03$), and a significant reduction in the incidence of advanced adenomas (OR 0.74, 95% CI 0.52 to 0.96, $p=0.03$).

More recently Bertagnoli *et al*⁷⁸ reported the results of a planned secondary analysis of a colorectal adenoma recurrence prevention trial where 679 of 2035 adenoma patients were randomised to receive placebo and the others varying dose of celecoxib. Analyses performed in the placebo arm of this study, i.e. those not receiving celecoxib, suggest that for patients at high risk of colorectal cancer, statins do not protect against colorectal adenoma (RR 1.24, 95% CI 0.99 to 1.56, $p=0.065$ for those who used statins at any dose during the 5 years follow-up) and may even increase the risk of developing colorectal adenomas (RR 1.39, 95% CI 1.04 to 1.86, $p=0.024$ for those having used statin for more than 3 years).

Thus, the effect of statins on adenomatous polyps remains controversial, with disparate results stemming from secondary analyses of interventional trials or three separate observational or case-control trials.

Additional mechanisms of statins that may underlie a benefit in CRC other than through a chemopreventive effect

Additionally to a potential chemopreventive effect, statins might also interfere with CRC by inhibiting the ability of cancer cells to metastasise, as it has been reported that, among patients diagnosed with colorectal cancer, statin users had a 30% decreased prevalence of metastasis compared to statin non-users (OR 0.7, 95% CI 0.4 to 0.9, $p<0.01$)⁷⁹ or enhancing the response to chemotherapeutic agents. It has been shown that pretreatment of different colon cancer cell lines with lovastatin significantly increases apoptosis induced by 5-fluorouracil (5-FU)

or cisplatin,⁸⁰ an effect described in both drug-sensitive and drug-resistant cell lines.⁸¹ Statins have also been shown, although it was not in colorectal cancer cells, to favour reversion of chemoresistance by reducing in P-glycoprotein expression a protein implicated in drug efflux.⁸² Statin use may thus overcome chemoresistance.

A randomised controlled trial comparing rosuvastatin to placebo in 5011 patients aged 60 or more with New York Heart Association class II, III or IV systolic heart failure followed for up to 36 months⁸³ showed identical cancer mortality rates in both groups (0.8%). Unfortunately the study did not provide results specifically addressing CRC mortality; moreover, included patients had a severely impaired cardiac function with about one third of patients dying within 36 months in both groups, not allowing for long term outcome, such as CRC, assessment. A recent case-control study of 1309 men with a new diagnosis of CRC (mean age 69 ± 1.1 (SE) years; 326 statin users, 983 statin non-users) suggested that in patients who presented to hospital with CRC, long-term use of statins was associated with less advanced tumour stage, a lower frequency of distant metastases, and an improved 5-year survival rate (37% vs 33%; OR 0.7, 95% CI 0.6 to 0.9, $p=0.03$).⁷⁹ This study is principally limited by possible recall bias, relatively small sample size, and the heterogeneous evaluation of CRC extension and the absence of information on cause of death. A retrospective study of 349 patients undergoing neoadjuvant chemoradiation for either locally advanced tumours or low-lying tumours requiring abdomino-perineal resection, compared results between patients on or off statins.⁸⁴ Only 9% used a statin, and overall, 23 non-statin users (7%) were found to have metastatic disease at the time of surgery, compared to none among statin users. In multivariable analysis, the odds ratio for statin use as predictor of complete histological response was 4.2 (95% CI 1.7 to 12.1, $p=0.003$).

A recent open-label phase II trial evaluating the efficacy and toxicity profile of conventional FOLFIRI chemotherapy in association with simvastatin in metastatic colorectal cancer patients⁸⁵ suggested this combination exhibited promising antitumour activity.

Other perspectives: the combination of statins with low-dose aspirin or non-steroidal anti-inflammatory drugs

If statin therapy by itself does not appreciably reduce the risk of CRC, the combination of statin plus another drug such as a non-steroidal anti-inflammatory agent (NSAID) or low dose aspirin might be considered. Randomised clinical trials have shown that cyclooxygenase-2 inhibitors can reduce colorectal adenoma recurrence,^{86 87} and epidemiological studies have suggested that their use is associated with a decreased risk of colorectal carcinoma.⁸⁸ Some studies have shown that statins and NSAIDs can act synergistically to inhibit cell cycle and promote apoptosis. Xiao *et al* showed a dramatic increase in

growth inhibition of cancer cell lines, from approximately 10% to 60%, when atorvastatin was combined with celecoxib, compared to both drugs used separately—an effect explained by a potentiation of G0/G1 arrest.⁸⁴ These findings were confirmed and expanded very recently by Yang *et al*⁴⁷ and support the need for further studies.

CONCLUSIONS

Although secondary analysis of randomised trials or cohort studies has failed to convincingly show a significant benefit attributable to statins in colorectal cancer, these agents have appeared beneficial, although modestly so, in case-control studies or when all studies were pooled together. They may thus have a role to play in colorectal cancer, perhaps more as adjuvant agents to chemotherapy, or in combination with drugs exhibiting different mechanism of action, such as NSAIDs or low-dose aspirin, or with antioxidants, for example.⁸⁹ Whereas experimental and clinical data suggest some differences in statin sensitivity across several types of cancers, such as of the breast, prostate or liver, no data support the hypothesis that any observable effect may be limited to certain cancers of particular molecular subtypes. Further research is needed to validate these interpretations and postulates, and assess more precisely the effect of statins in the prophylaxis of colorectal adenomas, or as combination agents with adjuvant or neo-adjuvant chemotherapy.

AB is the holder of the DG Kinnear Chair in Gastroenterology at McGill University, and is a Research Scholar (Chercheur National) of the Fonds de la Santé en Recherche du Québec.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES

1. Andrieu N, Launoy G, Guillois R, *et al*. Familial relative risk of colorectal cancer: a population-based study. *Eur J Cancer* 2003;**39**:1904–11.
2. Jemal A, Siegel R, Ward E, *et al*. Cancer statistics 2009. *CA Cancer J Clin* 2009;**59**:225–49.
3. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. *N Engl J Med* 2000;**342**:1960–8.
4. Graser A, Stieber P, Nagel D, *et al*. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. *Gut* 2009;**58**:241–8.
5. Hewitson P, Glasziou P, Watson E, *et al*. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* 2008;**103**:1541–9.
6. Jass JR. Diagnosis of hereditary non-polyposis colorectal cancer. *Histopathology* 1998;**32**:491–7.
7. Sieber OM, Lipton L, Crabtree M, *et al*. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med* 2003;**348**:791–9.
8. Alberts AW, Chen J, Kwon G, *et al*. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. *Proc Natl Acad Sci U S A* 1980;**77**:3957–61.
9. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;**339**:1349–57.

10. **Ridker PM**, Danielson E, Fonseca FA, *et al.* Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;**359**:2195–207.
11. **Zhang FL**, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. *Annu Rev Biochem* 1996;**65**:241–69.
12. **Bos JL**. ras oncogenes in human cancer: a review. *Cancer Res* 1989;**49**:4682–9.
13. **Prendergast GC**, Khosravi-Far R, Soliski PA, *et al.* Critical role of Rho in cell transformation by oncogenic Ras. *Oncogene* 1995;**10**:2289–96.
14. **Wong WW**, Dimitroulakos J, Minden MD, *et al.* HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. *Leukemia* 2002;**16**:508–19.
15. **Oliver MF**. Might treatment of hypercholesterolaemia increase non-cardiac mortality? *Lancet* 1991;**337**:1529–31.
16. **Neil HA**, Hawkins MM, Durrington PN, *et al.* Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. *Atherosclerosis* 2005;**179**:293–7.
17. **Neil A**, Cooper J, Betteridge J, *et al.* Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. *Eur Heart J* 2008;**29**:2625–33.
18. **Shrier I**, Boivin JF, Steele RJ, *et al.* Should meta-analyses of interventions include observational studies in addition to randomised controlled trials? A critical examination of underlying principles. *Am J Epidemiol* 2007;**166**:1203–9.
19. **Van Maele-Fabry G**, Libotte V, Willems J, *et al.* Review and meta-analysis of risk estimates for prostate cancer in pesticide manufacturing workers. *Cancer Causes Control* 2006;**17**:353–73.
20. **Gauthaman K**, Fong CY, Bongso A. Statins, stem cells, and cancer. *J Cell Biochem* 2009;**106**:975–83.
21. **Polakis P**. Wnt signalling and cancer. *Genes Dev* 2000;**14**:1837–51.
22. **Watson AJ**. Apoptosis and colorectal cancer. *Gut* 2004;**53**:1701–9.
23. **Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990;**61**:759–67.
24. **Miller M**, Smith D, Windsor A, *et al.* Survivin gene expression and prognosis in recurrent colorectal cancer. *Gut* 2001;**48**:137–8.
25. **De Oliveira Lima F**, De Oliveira Costa H, Barreza LF, *et al.* Immunoeexpression of inhibitors of apoptosis proteins and their antagonist SMAC/DIABLO in colorectal carcinoma: Correlation with apoptotic index, cellular proliferation and prognosis. *Oncol Rep* 2009;**22**:295–303.
26. **Shen W**, Wang CY, Wang XH, *et al.* Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. *J Exp Clin Cancer Res* 2009;**28**:81.
27. **Pignatelli M**. The adenomatous polyposis coli tumour suppressor gene regulates c-MYC transcription in colon cancer cells. *Gut* 1999;**44**:596.
28. **Sansom OJ**, Meniel VS, Muncan V, *et al.* Myc deletion rescues Apc deficiency in the small intestine. *Nature* 2007;**446**:676–9.
29. **Abaza MS**, Al-Saffar A, Al-Sawan S, *et al.* c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs. *Tumour Biol* 2008;**29**:287–303.
30. **Kim PJ**, Plescia J, Clevers H, *et al.* Survivin and molecular pathogenesis of colorectal cancer. *Lancet* 2003;**362**:205–9.
31. **Stanilov N**, Miteva L, Mintchev N, *et al.* High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. *Int J Colorectal Dis* 2009;**24**:151–7.
32. **Agarwal B**, Halmos B, Feoktistov AS, *et al.* Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. *Carcinogenesis* 2002;**23**:521–8.
33. **Cho SJ**, Kim JS, Kim JM, *et al.* Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. *Int J Cancer* 2008;**123**:951–7.
34. **Xiao H**, Zhang Q, Lin Y, *et al.* Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. *Int J Cancer* 2008;**122**:2115–24.
35. **West NJ**, Courtney ED, Poullis AP, *et al.* Apoptosis in the colonic crypt, colorectal adenoma, and manipulation by chemoprevention. *Cancer Epidemiol Biomarkers Prev* 2009;**18**:1680–7.
36. **Dirks AJ**, Jones KM. Statin-induced apoptosis and skeletal myopathy. *Am J Physiol Cell Physiol* 2006;**291**:C1208–12.
37. **Shibata MA**, Ito Y, Morimoto J, *et al.* Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. *Carcinogenesis* 2004;**25**:1887–98.
38. **Swamy MV**, Patlolla JM, Steele VE, *et al.* Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. *Cancer Res* 2006;**66**:7370–7.
39. **Kodach LL**, Bleuming SA, Peppelenbosch MP, *et al.* The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. *Gastroenterology* 2007;**133**:1272–81.
40. **Howe JR**, Bair JL, Sayed MG, *et al.* Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. *Nat Genet* 2001;**28**:184–7.
41. **Howe JR**, Mitros FA, Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. *Ann Surg Oncol* 1998;**5**:751–6.
42. **Brosens LA**, van Hattum A, Hyland LM, *et al.* Risk of colorectal cancer in juvenile polyposis. *Gut* 2007;**56**:965–7.
43. **Hardwick JC**, Van Den Brink GR, Bleuming SA, *et al.* Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon. *Gastroenterology* 2004;**126**:111–21.
44. **Kaneko R**, Tsuji N, Asanuma K, *et al.* Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. *J Biol Chem* 2007;**282**:19273–81.
45. **Dronamraju SS**, Coxhead JM, Kelly SB, *et al.* Cell kinetics and gene expression changes in colorectal cancer patients given resistant starch: a randomised controlled trial. *Gut* 2009;**58**:413–20.
46. **Hong MY**, Seeram NP, Zhang Y, *et al.* Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. *J Nutr Biochem* 2008;**19**:448–58.
47. **Yang Z**, Xiao H, Jin H, *et al.* Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. *Int J Cancer* 2010;**126**:852–63.
48. **Wachtershauser A**, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. *Carcinogenesis* 2001;**22**:1061–7.
49. **Denoyelle C**, Albanese P, Uzan G, *et al.* Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. *Cell Signal* 2003;**15**:327–38.
50. **Ukomadu C**, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. *J Biol Chem* 2003;**278**:43586–94.
51. **Carmeliet P**, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 2000;**407**:249–57.
52. **Staton CA**, Chetwood AS, Cameron IC, *et al.* The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. *Gut* 2007;**56**:1426–32.
53. **Izumi Y**, Shiota M, Kusakabe H, *et al.* Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. *Hypertens Res* 2009;**32**:675–9.
54. **Skalez-Rorowski A**, Walsh K. Statin therapy and angiogenesis. *Curr Opin Lipidol* 2003;**14**:599–603.
55. **Zhu XY**, Daghighi E, Chade AR, *et al.* Disparate effects of simvastatin on angiogenesis during hypoxia and inflammation. *Life Sci* 2008;**83**:801–9.
56. **Asakage M**, Tsuno NH, Kitayama J, *et al.* 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. *Anticancer Drugs* 2004;**15**:625–32.
57. **Wang HB**, Liu XP, Liang J, *et al.* Expression of RhoA and RhoC in colorectal carcinoma and its relations with clinicopathological parameters. *Clin Chem Lab Med* 2009;**47**:811–17.
58. **Boone B**, Van Gele M, Lambert J, *et al.* The role of RhoC in growth and metastatic capacity of melanoma. *J Cutan Pathol* 2009;**36**:629–36.
59. **Nubel T**, Dippold W, Kleinert H, *et al.* Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. *FASEB J* 2004;**18**:140–2.
60. **Tremblay PL**, Huot J, Auger FA. Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. *Cancer Res* 2008;**68**:5167–76.

61. **Kusama T**, Mukai M, Iwasaki T, *et al.* 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. *Gastroenterology* 2002;**122**:308–17.
62. **Paragh G**, Foris G, Paragh G Jr, *et al.* Different anticancer effects of fluvastatin on primary hepatocellular tumors and metastases in rats. *Cancer Lett* 2005;**222**:17–22.
63. **Narisawa T**, Fukaura Y, Terada K, *et al.* Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. *Carcinogenesis* 1994;**15**:2045–8.
64. **Bjerre LM**, LeLorier J. Do statins cause cancer? A meta-analysis of large randomised clinical trials. *Am J Med* 2001;**110**:716–23.
65. **Dale KM**, Coleman CI, Henyan NN, *et al.* Statins and cancer risk: a meta-analysis. *JAMA* 2006;**295**:74–80.
66. **Stein EA**, Corsini A, Gimpelewicz CR, *et al.* Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract* 2006;**60**:1028–34.
67. **Bonovas S**, Filioussi K, Flordellis CS, *et al.* Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. *J Clin Oncol* 2007;**25**:3462–8.
68. **Browning DR**, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. *Int J Cancer* 2007;**120**:833–43.
69. **Taylor ML**, Wells BJ, Smolak MJ. Statins and cancer: a meta-analysis of case-control studies. *Eur J Cancer Prev* 2008;**17**:259–68.
70. **Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care.** The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002;**288**:2998–3007.
71. **Kaneta S**, Satoh K, Kano S, *et al.* All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. *Atherosclerosis* 2003;**170**:237–43.
72. **Gauthaman K**, Richards M, Wong J, *et al.* Comparative evaluation of the effects of statins on human stem and cancer cells in vitro. *Reprod Biomed Online* 2007;**15**:566–81.
73. **Singh H**, Mahmud SM, Turner D, *et al.* Long-term use of statins and risk of colorectal cancer: a population-based study. *Am J Gastroenterol* 2009;**104**:3015–23.
74. **Wei JT**, Mott LA, Baron JA, *et al.* HMG-CoA reductase inhibitor use and recurrence of colorectal adenomas. *Gastroenterology* 2003;**124**:A241-A.
75. **Fiske WH**, Smalley WE, Shrubsole M, *et al.* Regular Statin use and colorectal adenoma risk. *Gastroenterology* 2007;**132**:A441-A.
76. **Khan G**, Qazi N, Asokan S, *et al.* Statins increase the risk of colorectal adenomatous polyps. *Gastroenterology* 2006;**130**:A185-A.
77. **Siddiqui AA**, Nazario H, Mahgoub A, *et al.* The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. *Digestion* 2009;**79**:17–22.
78. **Bertagnoli MM**, Hsu M, Hawk ET, *et al.* Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. *Cancer Prev Res (Phila Pa)* 2010;**3**:588–96.
79. **Siddiqui AA**, Nazario H, Mahgoub A, *et al.* For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. *Dig Dis Sci* 2009;**54**:1307–11.
80. **Agarwal B**, Bhendwal S, Halmos B, *et al.* Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. *Clin Cancer Res* 1999;**5**:2223–9.
81. **Wang W**, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. *FEBS Lett* 2002;**531**:415–20.
82. **Connelly-Smith L**, Pattinson J, Grundy M, *et al.* P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. *Exp Hematol* 2007;**35**:1793–800.
83. **Kjekshus J**, Apetrei E, Barrios V, *et al.* Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;**357**:2248–61.
84. **Katz MS**, Minsky BD, Saltz LB, *et al.* Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. *Int J Radiat Oncol Biol Phys* 2005;**62**:1363–70.
85. **Lee J**, Jung KH, Park YS, *et al.* Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. *Cancer Chemother Pharmacol* 2009;**64**:657–63.
86. **Baron JA**, Sandler RS, Bresalier RS, *et al.* A randomised trial of rofecoxib for the chemoprevention of colorectal adenomas. *Gastroenterology* 2006;**131**:1674–82.
87. **Bertagnoli MM**, Eagle CJ, Zauber AG, *et al.* Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. *Cancer Prev Res (Phila Pa)* 2009;**2**:310–21.
88. **Rahme E**, Barkun AN, Toubouti Y, *et al.* The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. *Gastroenterology* 2003;**125**:404–12.
89. **Arber N**, Levin B. Chemoprevention of colorectal neoplasia: the potential for personalized medicine. *Gastroenterology* 2008;**134**:1224–37.
90. **Shepherd J**, Cobbe SM, Ford I, *et al.* Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med* 1995;**333**:1301–7.
91. **Sacks FM**, Pfeffer MA, Moye LA, *et al.* The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;**335**:1001–9.
92. **Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations.** the LIPID trial follow-up. *Lancet* 2002;**359**:1379–87.
93. **Downs JR**, Clearfield M, Weis S, *et al.* Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;**279**:1615–22.
94. **Shepherd J**, Blauw GJ, Murphy MB, *et al.* Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;**360**:1623–30.
95. **Anon.** MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002;**360**:7–22.
96. **Strandberg TE**, Pyörälä K, Cook TJ, *et al.* Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). *Lancet* 2004;**364**:771–7.
97. **Colhoun HM**, Betteridge DJ, Durrington PN, *et al.* Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004;**364**:685–96.
98. **Nakamura H**, Arakawa K, Itakura H, *et al.* Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. *Lancet* 2006;**368**:1155–63.
99. **Blais L**, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. *Arch Intern Med* 2000;**160**:2363–8.
100. **Kaye JA**, Jick H. Statin use and cancer risk in the General Practice Research Database. *Br J Cancer* 2004;**90**:635–7.
101. **Graaf MR**, Beiderbeck AB, Egberts AC, *et al.* The risk of cancer in users of statins. *J Clin Oncol* 2004;**22**:2388–94.
102. **Khurana V**, Jagannathan S, Chalasani R, *et al.* Statins do not reduce colon cancer risk in humans: A case control study in half a million veterans. *American Journal of Gastroenterology* 2004;**99**:746.
103. **Poynter JN**, Gruber SB, Higgins PD, *et al.* Statins and the risk of colorectal cancer. *N Engl J Med* 2005;**352**:2184–92.
104. **Rubin DT**, Blumentals WA, Sheer RL, *et al.* Statins and risk of colorectal cancer: Results from a large case-control study. *Am J Gastroenterol* 2005;**100**:1086.
105. **Coogan PF**, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. *J Natl Cancer Inst* 2007;**99**:32–40.
106. **Vinogradova Y**, Hippisley-Cox J, Coupland C, *et al.* Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. *Gastroenterology* 2007;**133**:393–402.
107. **Yang YX**, Hennessy S, Probert K, *et al.* Chronic statin therapy and the risk of colorectal cancer. *Pharmacoepidemiol Drug Saf* 2008;**17**:869–76.
108. **Boudreau DM**, Koehler E, Rulyak SJ, *et al.* Cardiovascular medication use and risk for colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2008;**17**:3076–80.
109. **Robertson DJ**, Riis A, Friis S, *et al.* Statin use and risk of colorectal cancer. A population based case control study. *Gastroenterology* 2008;**134**:A59-A.
110. **Shadman M**, Newcomb PA, Hampton JM, *et al.* Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. *World J Gastroenterol* 2009;**15**:2336–9.

111. **Hachem C**, Morgan R, Johnson M, *et al*. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. *Am J Gastroenterol* 2009;**104**:1241–8.
112. **Friis S**, Poulsen AH, Johnsen SP, *et al*. Cancer risk among statin users: A population-based cohort study. *Int J Cancer* 2005;**114**:643–7.
113. **Jacobs EJ**, Rodriguez C, Brady KA, *et al*. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. *J Natl Cancer Inst* 2006;**98**:69–72.
114. **Setoguchi S**. Statins and cancer in the elderly. *Cardiology Review* 2007;**24**:13–16.
115. **Karp I**, Behloul H, LeLorier J, *et al*. Statins and cancer risk. *Am J Med* 2008;**121**:302–9.
116. **Farwell WR**, Scranton RE, Lawler EV, *et al*. The association between statins and cancer incidence in a veterans population. *J Natl Cancer Inst* 2008;**100**:134–9.
117. **Flick ED**, Habel LA, Chan KA, *et al*. Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. *Drugs* 2009;**69**:1445–57.
118. **Haukka J**, Sankila R, Klaukka T, *et al*. Incidence of cancer and statin usage—record linkage study. *Int J Cancer* 2010;**126**:279–84.